Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14
Annovis Bio, Inc. (ANVS)
Company Research
Source: GlobeNewswire
BERWYN, Pa., April 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced today its CEO Maria Maccecchini, Ph.D. will share insight into the company’s recent developments during an investor webinar on Tuesday April 14, 2020 at 4:05 p.m. ET. A live Q&A session with Dr. Maccecchini will follow the presentation. To participate in the webinar, please register at: https://www.redchip.com/corporate/webinar_register/56 Questions can be pre-submitted to victor@redchip.com or online during the event. About Annovis Bio Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Bio, Inc. (NYSE: ANVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
- Annovis Bio, Inc. (NYSE: ANVS) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $36.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
- Annovis Bio: Searching For Efficacy In Alzheimer's Disease [Seeking Alpha]Seeking Alpha
- UPDATE 1-Annovis' Alzheimer's treatment helps improve cognition in trial [Yahoo! Finance]Yahoo! Finance
- Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
ANVS
Earnings
- 8/14/23 - Beat
ANVS
Sec Filings
- 4/29/24 - Form ARS
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- ANVS's page on the SEC website